All In Biotech

Drug Trial Radar · NCT07220629

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide Plus a Reduced Calorie Diet and Increased Physical Activity in Participants With Obesity

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Oct 2, 2025

Primary completion

Aug 21, 2026

Study completion Aug 21, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

Conditions

  • Obesity

Interventions

  • NT-0796Drug

    Orally administered capsules

  • PlaceboDrug

    Orally administered capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs.Time frame: Baseline to Week 24

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Mesa, Arizona

  • Investigative Site

    Hialeah, Florida

  • Investigative Site

    Jacksonville, Florida

  • Investigative Site

    Miami, Florida

  • Investigative Site

    Marrero, Louisiana

  • Investigative Site

    Columbus, Ohio

  • Investigative Site

    Seabrook, Texas

  • Investigative Site

    Salt Lake City, Utah

  • Investigative Site

    Manassas, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.